Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Immunome Inc (NQ: IMNM )

12.23 +0.03 (+0.21%)
Streaming Delayed Price Updated: 3:29 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunome Inc

< Previous 1 2 3 Next >
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
From Immunome, Inc.
Via Business Wire
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
From Immunome, Inc.
Via Business Wire
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
From Immunome, Inc.
Via Business Wire
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
From Immunome, Inc.
Via Business Wire
Immunome Appoints Phil Tsai as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
Immunome Announces Completion of Purchase of Assets from Atreca
From Immunome, Inc.
Via Business Wire
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
From Immunome, Inc.
Via Business Wire
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Immunome to Present at 2024 Bank of America Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Appoints Kinney Horn as Chief Business Officer
From Immunome, Inc.
Via Business Wire
Immunome Appoints Sandra M. Swain to Board of Directors
From Immunome
Via Business Wire
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
From Immunome, Inc.
Via Business Wire
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
From Immunome, Inc.
Via Business Wire
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
From Immunome, Inc.
Via Business Wire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
From Ayala Pharmaceuticals
Via GlobeNewswire
Immunome to Participate in the Leerink Partners Global Biopharma Conference
From Immunome, Inc.
Via Business Wire
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Immunome, Inc.
Via Business Wire
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Immunome, Inc.
Via Business Wire
Immunome Announces Pricing of Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Immunome, Inc.
Via Business Wire
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile 
From Ayala Pharmaceuticals
Via GlobeNewswire
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Immunome, Inc.
Via Business Wire
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
From Immunome, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.